BRPI1013771A2 - "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." - Google Patents
"células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."Info
- Publication number
- BRPI1013771A2 BRPI1013771A2 BRPI1013771A BRPI1013771A BRPI1013771A2 BR PI1013771 A2 BRPI1013771 A2 BR PI1013771A2 BR PI1013771 A BRPI1013771 A BR PI1013771A BR PI1013771 A BRPI1013771 A BR PI1013771A BR PI1013771 A2 BRPI1013771 A2 BR PI1013771A2
- Authority
- BR
- Brazil
- Prior art keywords
- designed
- stem cells
- mesenchymal stem
- treat tumors
- tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16878709P | 2009-04-13 | 2009-04-13 | |
| PCT/EP2010/054844 WO2010119039A1 (en) | 2009-04-13 | 2010-04-13 | Engineered mesenchymal stem cells and method of using same to treat tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013771A2 true BRPI1013771A2 (pt) | 2016-04-05 |
Family
ID=42270435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013771A BRPI1013771A2 (pt) | 2009-04-13 | 2010-04-13 | "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9434925B2 (enExample) |
| EP (1) | EP2419113B1 (enExample) |
| JP (1) | JP5727458B2 (enExample) |
| KR (1) | KR20120088542A (enExample) |
| CN (1) | CN102695517B (enExample) |
| AU (1) | AU2010237130B2 (enExample) |
| BR (1) | BRPI1013771A2 (enExample) |
| CA (1) | CA2758120C (enExample) |
| IL (1) | IL215581A0 (enExample) |
| RU (1) | RU2539099C2 (enExample) |
| SG (1) | SG175127A1 (enExample) |
| WO (1) | WO2010119039A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
| KR102053385B1 (ko) * | 2012-02-01 | 2019-12-06 | 포항공과대학교 산학협력단 | 12량체 ｔｒａｉｌ 및 ｈｓｖ-ｔｋ 자살유전자를 동시에 발현하는 벡터 및 이를 이용한 항암 줄기세포 치료제 |
| US20130203166A1 (en) * | 2012-02-06 | 2013-08-08 | Protobios Llc | Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5 |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| US20140065110A1 (en) | 2012-08-31 | 2014-03-06 | The Regents Of The University Of California | Genetically modified msc and therapeutic methods |
| DK4389764T3 (da) * | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| US10472647B2 (en) | 2012-12-21 | 2019-11-12 | The Administrators Of The Tulane Educational Fund | Primary mesenchymal stem cells as a vaccine platform |
| WO2015100268A1 (en) * | 2013-12-23 | 2015-07-02 | The Regents Of The University Of California | Mesenchymal stem cells for targeted cancer therapy |
| KR20160107303A (ko) * | 2014-01-17 | 2016-09-13 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 활성 작용제 전달의 강화 방법 |
| US20170239297A1 (en) | 2014-08-18 | 2017-08-24 | Apceth Gmbh & Co. Kg | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
| ES2841075T3 (es) * | 2014-10-24 | 2021-07-07 | Calidi Biotherapeutics Inc | Enfoque de inmunoterapia de combinación para el tratamiento del cáncer |
| CN104622903B (zh) * | 2015-01-20 | 2018-10-09 | 奥思达干细胞有限公司 | 抗恶性黑色素瘤的干细胞制剂及其制备方法 |
| US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| WO2016138340A1 (en) * | 2015-02-27 | 2016-09-01 | Saint Louis University | Tumor suppressor sall1 as a therapeutic agent for treating cancer |
| US20180037868A1 (en) * | 2015-02-27 | 2018-02-08 | Apceth Gmbh & Co. Kg | Genetically modified mesenchymal stem cell expressing klotho |
| WO2016146819A1 (en) * | 2015-03-18 | 2016-09-22 | Apceth Gmbh & Co. Kg | Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| HK1248588A1 (zh) | 2015-08-11 | 2018-10-19 | Calidi Biotherapeutics, Inc. | 用於癌症治疗中的天花疫苗 |
| WO2017036925A1 (en) * | 2015-08-28 | 2017-03-09 | Apceth Gmbh & Co. Kg | Mesenchymal stem cells for the treatment of metastatic liver disease |
| IL297238B2 (en) | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| AU2017277499B2 (en) * | 2016-06-07 | 2022-07-28 | The Pacific Heart, lung & Blood Institute | Compositions and methods for treating cancer |
| WO2017213697A1 (en) | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| CA3028982A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| WO2018017882A1 (en) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Viral vectors for treating parkinson's disease |
| AU2017354272A1 (en) | 2016-11-03 | 2019-05-23 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| KR20190141695A (ko) | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
| US12559769B2 (en) | 2017-06-16 | 2026-02-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| WO2019195142A1 (en) | 2018-04-03 | 2019-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Mesenchymal stem cells comprising a chimeric antigen receptor (car) for treating inflammatory and autoimmune diseases |
| KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
| EP3806864A4 (en) * | 2018-06-14 | 2022-05-25 | Loma Linda University | GENETIC HEMATOPOIETIC STEM CELLS FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA |
| CA3116138A1 (en) | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EP3876952A4 (en) | 2018-11-05 | 2022-08-24 | American Gene Technologies International Inc. | VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| US20220241337A1 (en) * | 2019-02-22 | 2022-08-04 | The Trustees Of Columbia University In The City Of Newyork | Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents |
| SG10201902002SA (en) * | 2019-03-06 | 2020-10-29 | Nat Univ Singapore | Non-viral modification of mesenchymal stem cells |
| EP4556072A3 (en) * | 2019-08-23 | 2025-06-11 | Orbsen Therapeutics Limited | Compositions for monocyte and macrophage polarization and methods of use |
| EP3995130A1 (en) | 2020-11-06 | 2022-05-11 | JunctuCell Biomed Manufacturing GmbH | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
| US20230414730A1 (en) | 2020-11-06 | 2023-12-28 | Aatec Medical Gmbh | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6265564B1 (en) * | 1996-08-02 | 2001-07-24 | Regeneron Pharmaceuticals, Inc. | Expressed ligand-vascular intercellular signalling molecule |
| US7098185B2 (en) * | 1998-05-18 | 2006-08-29 | University College London | Polypeptide hormone phosphatonin |
| WO2001091802A1 (en) * | 2000-05-30 | 2001-12-06 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
| WO2002069953A1 (en) * | 2001-03-01 | 2002-09-12 | The Board Of Regents Of The University Of Texas System | Methods of treating lung inflammation |
| US20030165579A1 (en) * | 2002-02-27 | 2003-09-04 | Chih-Hui Lin | Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers |
| EP1544213B1 (en) * | 2003-12-19 | 2008-02-20 | Charité - Universitätsmedizin Berlin | Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases |
| JP2006194752A (ja) * | 2005-01-14 | 2006-07-27 | Sumitomo Metal Mining Co Ltd | Ｘ線回折測定における試料固定方法および試料固定具 |
| KR101022401B1 (ko) * | 2005-09-29 | 2011-03-15 | 아주대학교산학협력단 | 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물 |
| ES2507507T3 (es) | 2007-05-24 | 2014-10-15 | Apceth Gmbh & Co. Kg | Células madre mesenquimales CD34 negativas modificadas genéticamente para el tratamiento de tumores |
-
2010
- 2010-04-13 JP JP2012505149A patent/JP5727458B2/ja active Active
- 2010-04-13 CN CN201080026333.1A patent/CN102695517B/zh not_active Expired - Fee Related
- 2010-04-13 KR KR1020117026918A patent/KR20120088542A/ko not_active Ceased
- 2010-04-13 BR BRPI1013771A patent/BRPI1013771A2/pt not_active IP Right Cessation
- 2010-04-13 CA CA2758120A patent/CA2758120C/en not_active Expired - Fee Related
- 2010-04-13 AU AU2010237130A patent/AU2010237130B2/en not_active Ceased
- 2010-04-13 EP EP10713933.9A patent/EP2419113B1/en not_active Not-in-force
- 2010-04-13 SG SG2011073418A patent/SG175127A1/en unknown
- 2010-04-13 RU RU2011146048/10A patent/RU2539099C2/ru not_active IP Right Cessation
- 2010-04-13 WO PCT/EP2010/054844 patent/WO2010119039A1/en not_active Ceased
- 2010-04-13 US US13/264,084 patent/US9434925B2/en not_active Expired - Fee Related
-
2011
- 2011-10-06 IL IL215581A patent/IL215581A0/en unknown
-
2016
- 2016-08-31 US US15/253,353 patent/US20170015976A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170015976A1 (en) | 2017-01-19 |
| JP5727458B2 (ja) | 2015-06-03 |
| JP2012523243A (ja) | 2012-10-04 |
| EP2419113B1 (en) | 2017-05-10 |
| KR20120088542A (ko) | 2012-08-08 |
| US20120087901A1 (en) | 2012-04-12 |
| SG175127A1 (en) | 2011-11-28 |
| AU2010237130A1 (en) | 2011-11-03 |
| CA2758120A1 (en) | 2010-10-21 |
| RU2539099C2 (ru) | 2015-01-10 |
| CN102695517B (zh) | 2015-01-28 |
| RU2011146048A (ru) | 2013-05-20 |
| WO2010119039A1 (en) | 2010-10-21 |
| US9434925B2 (en) | 2016-09-06 |
| EP2419113A1 (en) | 2012-02-22 |
| AU2010237130B2 (en) | 2015-01-29 |
| CN102695517A (zh) | 2012-09-26 |
| CA2758120C (en) | 2014-08-19 |
| IL215581A0 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0909817A2 (pt) | uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos | |
| BR112012016203A2 (pt) | "métodos para melhoria da proliferaçõ e atividade das células exterminadoras naturais" | |
| SMT201600050B (it) | Mezzi e metodi per trattare il dlbcl | |
| BR112014005355A2 (pt) | células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença | |
| BRPI0924921A2 (pt) | Métodos de isolar células-tronco mesequimais, de promover proliferação das referidas células e de produção de tecidos diferenciados | |
| MX379016B (es) | Composiciones y metodos para tratar enfermedad de gaucher. | |
| CY2017021I2 (el) | Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9 | |
| CL2013000238A1 (es) | Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos. | |
| BRPI0807132A2 (pt) | enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas | |
| BRPI1009871A2 (pt) | terapia para promover o crescimento celular | |
| BRPI1009263A2 (pt) | alfa-amilases relacionadas com cepa de bacillus megaterium dsm90 e métodos de uso das mesmas. | |
| PT2426148E (pt) | Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue | |
| CL2014001299A1 (es) | Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor. | |
| BR112012009921A2 (pt) | métodos para reprogramar células e usos do mesmos | |
| DK3130923T3 (da) | Terapeutiske fremgangsmåder i forbindelse med cancerstamceller | |
| BRPI0921433A2 (pt) | uso de anticorpos anti-cs1 para o tratamento de linfomas raros | |
| BRPI1011655A2 (pt) | uso de lcat para tratar anemia e disfunção de glóbulos vermelhos | |
| BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
| BRPI0912292A2 (pt) | composições e métodos para o uso de células no tratamento do tecido cardíaco. | |
| BR112012000882A2 (pt) | Preparação cosmética capilar e método para aplicação. | |
| BR112013001089A2 (pt) | composição de meio de cultura e método para cultivar células tronco mesenquimais derivadas de âmnio | |
| BRPI1014800A8 (pt) | "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas" | |
| SG175127A1 (en) | Engineered mesenchymal stem cells and method of using same to treat tumors | |
| BRPI0920891A2 (pt) | misturas de alfa-amilase e métodos para uso das referidas misturas | |
| AR079889A1 (es) | Antagonistas de wnt y metodos de tratamiento y deteccion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |